Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies

Author
Buffels, R.
Siva, A.
Nicholas, R.
Bernasconi, C.
Kuhelj, R.
Vermersch, P.
Comi, G.
Oreja-Guevara, C.
Wiendl, H.
Van Wijmeersch, B.
Eralinna, J. -P.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/37851
Collections